Bluefin Merger Subsidiary, Inc. is a special-purpose, wholly owned subsidiary of Roche Holdings, Inc., formed to facilitate Roche’s acquisition of 89bio, Inc. It serves as the designated merger vehicle in the transaction structure.
The company has no independent operations or products and exists solely to complete the merger, after which it is typically consolidated into the target entity as part of Roche. While not an operator in the chemicals sector, its role is relevant to life sciences deal activity that interfaces with bioprocessing, therapeutics development, and related supply chains.
None yet. When a new project in the record names Bluefin Merger Subsidiary, Inc. as owner, partner or investor, it shows here.
Roche's subsidiary accepted tendered shares of 89bio, planning a merger to make 89bio a wholly owned subsidiary, delisting it from Nasdaq.
Tender offer expires Oct 29, 2025. Includes CVR up to $6.00. Requires majority share tender, no financing condition. Second-step merger follows at same terms. Completion expected Q4 2025.
